For decades, the field of immunology was a black box. Leading experts in science and medicine had only a basic understanding of the powerful complexity of the human immune system. Everything changed in 1983 when a...
Biopharma
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative
– Long acting Relaxin is powered by Ambrx technology SAN DIEGO, California, July 16, 2019 –Ambrx Inc, today announced that Bristol-Myers Squibb Company (“BMS”) has initiated a phase I clinical trial to evaluate...
